周四，H.C. Wainwright重申对Lyell Immunopharma（NASDAQ:LYEL）股票的中性评级，维持目标价为$1.00。该股目前交易价格为$0.67，过去一年经历了显著波动，下跌超过71%。根据InvestingPro分析，该公司资产负债表稳健，现金多于债务，但目前正在消耗现金储备。分析师报告重点关注Lyell ...

Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a next-generation dual-targeting CD19/CD20 CAR T-cell ...

Reports cash, cash equivalents and marketable securities as of December 31 were $383.5M compared to $562.7M as of December 31, 2023. Lyell ...

Lyell Immunopharma (NASDAQ:LYEL – Get Free Report)‘s stock had its “neutral” rating reissued by stock analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports.

SA Health officials apologise to a man who waited 15 hours to be seen at an Adelaide emergency department after presenting ...

Lakwan Hannah of Rochester is facing several charges for allegedly shooting and killing Jared Perry, 29, and Marquis Chambers ...

March 11, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer ...

On Thursday, H.C. Wainwright reiterated a Neutral rating on Lyell Immunopharma (NASDAQ:LYEL) shares, with a steady price target of $1.00. The stock, currently trading at $0.67, has experienced ...

A man suffering a suspected stroke waited 15 hours at Lyell McEwin Hospital before giving up – as meth-affected patients in ...